Saito Tatsuya, Tanaka Yasuko, Morishita Yoshiyuki, Ishibashi Kenichi
Department of Pathophysiology, Faculty of Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo 204-8588, Japan.
Department of Nephrology, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Biochem Biophys Rep. 2017 Nov 23;13:17-21. doi: 10.1016/j.bbrep.2017.11.003. eCollection 2018 Mar.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is caused by the mutation of polycystins (PC-1 or PC-2), in which cysts start from the collecting duct to extend to all nephron segments with eventual end stage renal failure. The cyst development is attenuated by a vasopressin V2 receptor antagonist tolvaptan which, however, will not affect proximal tubule cysts devoid of V2 receptor. Aquaporin-11 (AQP11) is expressed selectively in the proximal tubule of the kidney and AQP11-null kidneys have a disruptive PC-1 trafficking to the plasma membrane to develop polycystic kidneys. Here, we analyzed AQP11-null kidneys at the beginning of cyst formation by quantitative proteomic analysis using Tandem Mass Tag (TMT). Among ~ 1200 identified proteins, 124 proteins were differently expressed by > 1.5 or < 0.8 fold change. A pancreatic stone inhibitor or a growth factor, lithostathine-1 (Reg1) was most enhanced by 5 folds which was confirmed by western blot, while mitochondria-related proteins were downregulated. The identified proteins will be new target molecules for the treatment of proximal tubular cysts and helpful to explore the functional roles of AQP11 in the kidney.
常染色体显性多囊肾病(ADPKD)由多囊蛋白(PC-1或PC-2)突变引起,囊肿从集合管开始延伸至所有肾单位节段,最终发展为终末期肾衰竭。血管加压素V2受体拮抗剂托伐普坦可减缓囊肿的发展,然而,它不会影响缺乏V2受体的近端肾小管囊肿。水通道蛋白11(AQP11)在肾脏近端小管中选择性表达,缺乏AQP11的肾脏会出现PC-1向质膜转运障碍,从而形成多囊肾。在此,我们通过使用串联质谱标签(TMT)的定量蛋白质组学分析,在囊肿形成初期对缺乏AQP11的肾脏进行了分析。在约1200种鉴定出的蛋白质中,有124种蛋白质的表达差异超过1.5倍或低于0.8倍。一种胰腺结石抑制剂或生长因子,即胰石蛋白-1(Reg1)的表达增强最为明显,增加了5倍,这一点通过蛋白质免疫印迹得到了证实,而与线粒体相关的蛋白质表达下调。所鉴定出的蛋白质将成为治疗近端肾小管囊肿的新靶分子,并有助于探索AQP11在肾脏中的功能作用。